Skip to main content

Table 3 Risk for development of RA in individuals before the onset of any symptoms of disease (n = 370)

From: Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis

Antibodies Frequency OR (95% CI) OR (95% CI) OR (95% CI)
  N (%)   Adjusted for smoking Adjusted for HLA-SE
    (n = 348) (n = 366)
Anti-CCP2 129 (34.9) 21.83 (12.33–38.67) 21.69 (11.96–39.33) 19.52 (10.96–34.79)
Anti-CEP-1/Eno5-21 107 (28.9) 6.27 (4.16–9.43) 5.69 (3.74–8.66) 5.57 (3.67–8.46)
Anti-CitC1359-369 47 (13.1) 3.32 (2.00–5.50) 3.04 (1.82–5.10) 3.27 (1.94–5.50)
Anti-Fibα580-600 (591) 31 (8.7) 1.46 (0.88–2.41) 1.39 (0.82–2.36) 1.54 (0.91–2.61)
Anti-Fibα563-583 (573) 40 (10.8) 2.20 (1.34–3.60) 2.10 (1.25–3.53) 2.15 (1.29–3.57)
Anti-Fibβ62-81a (72) 43 (11.6) 4.06 (2.30–7.16) 4.42 (2.47–7.91) 3.44 (1.92–6.17)
Anti-Fibβ62-81b (74) 57 (15.9) 10.68 (5.38–21.22) 10.05 (5.02–20.10) 9.48 (4.72–19.05)
Anti-Fibβ36-52 110 (29.7) 5.97 (4.01–8.88) 6.07 (4.00–9.22) 5.66 (3.76–8.51)
Anti-CCP-1/Fil307-324 97 (26.2) 11.64 (6.82–19.88) 12.10 (6.94–21.10) 10.39 (6.03–17.90)
Anti-Vim60-75 48 (13.0) 2.61 (1.63–4.19) 2.37 (1.45–3.88) 2.50 (1.54–4.08)
Anti-Vim2-17 29 (7.0) 1.90 (1.06–3.40) 1.55 (0.85–2.85) 1.85 (1.01–.3.39)
  1. OR= odds ratio, CI= confidence intervals, anti-CCP2=anti-cyclic citrullinated peptide antibodies, anti CEP-1/Eno5-21= antibodies against α-Enolase, anti-citC1359-369= antibodies against collagen type II aa 359-369 with two citrulline residues, anti- Fibα580-600=antibodies against fibrinogen (Fib) Fibα580-600, anti-Fibα561-583= antibodies against Fibα561-583, anti- Fibβ62-81a(72)=antibodies against Fibβ62-81a(72), anti-Fibβ62-81b(74)= antibodies against Fibβ62-81b(74), anti-Fibβ36-52= antibodies against Fibβ36-52, anti- CCP-1/Fil307-324= antibodies against filaggrin, anti- Vim60-75= antibodies against vimentin (Vim)60-75, anti-Vim2-17= antibodies against Vim 2-17.